2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6004 Post-transplant cyclophosphamide (PTCy) preserves lymph node architecture and immune functions

Leena Babiker, PhD, MS, Léolène Carrington, PhD2, Brandon Zhou3, Jason Shoush4, Anneka Allman5, Katlyn Lederer6, Yunlin Zhang7, Malay Haldar8, Micheal J May9, Laura A. Vella, MD, PhD, MSTR10, Ivan Maillard, MD, PhD11
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Kite Pharma, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Lymph nodes (LNs) are critical sites of immune cell trafficking, activation, and homeostasis. Our prior data in mouse models of allogeneic hematopoietic cell transplantation (allo-HCT) indicate that GVHD can lead to LN damage. In GVHD, LN display loss of stromal cells, disrupted microanatomic organization, and reduced entry of naïve lymphocytes. Together these GVHD-associated changes create a tissue-level barrier to healthy immune reconstitution. Although post-transplant cyclophosphamide (PTCy) is widely used to prevent GVHD, whether it preserves LN structure and function and thereby supports functional immune recovery remains unclear. We hypothesized that PTCy protects the LN microenvironment, allowing restoration of naïve lymphocyte trafficking and adaptive immune responses during GVHD.

We developed a sublethal, major histocompatibility complex (MHC)–mismatched mouse model of allo-HCT with relative preservation of thymic function, so that LN homeostasis could be studied in the presence of ongoing T cell production (C57BL/6 into lethally irradiated BALB/c × C57BL/6 F1 recipients). We compared recipients of T-cell-depleted bone marrow (TCD BM) vs. TCD BM + T cells (GVHD) vs. TCD BM + T cells treated with PTCy at 25 mg/kg on days +3 and +4 after allo-HCT. GVHD markedly impaired the 12-hour homing of adoptively transferred polyclonal lymphocytes and naïve T cells to peripheral LNs and was associated with reduced numbers of endogenous naïve lymphocytes and recent thymic emigrants 21 days after allo-HCT. PTCy restored naïve T- and B-cell reconstitution, increased recent thymic emigrants within LNs, and improved lymphocyte homing. PTCy also preserved LN organization, including B-cell follicles and T-cell zones, and partially restored the abundance of lymph node fibroblastic reticular cells and high endothelial venules. Following protein immunization with ovalbumin/alum at day 40 after allo-HCT, PTCy-treated mice exhibited increased T follicular helper cells and germinal center B cells after immunization compared with untreated GVHD mice, indicating partial recovery of vaccine responsiveness and immune competence.

We next evaluated the mechanisms underlying impaired LN trafficking in GVHD without PTCy. Multiple MHC mismatched and minor histocompatibility antigen–mismatched GVHD models caused early depletion of CD157hi fibroblastic reticular cells and lymphatic endothelial cell subsets, impaired lymphatic drainage and conduit access, and reduced DC trafficking through afferent lymphatics as early as day 14 after all-HCT. High endothelial venules (HEVs), which mediate lymphocyte entry from the blood, displayed flattened morphology and reduced peripheral node addressin expression (PNAd). Residual DCs exhibited decreased binding to an LTβR–Fc fusion protein, consistent with reduced cell-surface expression of the trimeric LTβR ligand lymphotoxin-α1β2. Bulk RNA sequencing of sorted LN DCs further demonstrated reduced Lta and Ltb mRNA in GVHD compared with T-cell-depleted controls, supporting attenuated DC-derived lymphotoxin signaling. Whereas T-cell-depleted controls retained a mixture of donor- and host-derived DCs, GVHD LNs were predominantly repopulated by donor-derived DCs, which displayed lower LTβR–Fc binding than residual host-derived DCs. To determine whether this pathway was therapeutically reversible, mice received Flt3 ligand–cultured, LPS-activated bone marrow–derived DCs one day after transplantation or an agonistic lymphotoxin-β receptor antibody administered every other day for one week beginning on day +7. Both interventions partially restored HEV differentiation and PNAd expression and improved lymphocyte homing to LNs by day 14 after transplantation.

Together, these findings demonstrate that PTCy partially preserves LN architecture, lymphocyte trafficking, and vaccine responsiveness during GVHD. They further identify disruption of the DC–LTβR–HEV axis as a mechanistic contributor to LN dysfunction and a potential target for improving healthy immune reconstitution after allo-HCT. Future research will investigate to what extent LN preservation contributes to the beneficial immunomodulation provided by PTCy after allo-HCT.

Leena Babiker, PhD, MS: No relevant conflicts of interest to declare.